{"success":true,"data":{"pressRelease":{"id":"20875","rtpr_id":"nGNX3nMDsV","ticker":"VRCA","exchange":"NASDAQ","all_tickers":["VRCA"],"title":"Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026","author":"Globe Newswire","published_at":"2026-05-05T12:00:00.843Z","article_body":"WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals\nInc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics\ncompany developing and commercializing medications for the treatment of\ndermatological diseases, including skin cancers, today announced that it will\nhost a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 12,\n2026, to discuss the Company's financial results for the first quarter ending\nMarch 31, 2026, and provide a corporate update.\n\nIndividuals may participate in the live call via telephone by dialing\n1-833-316-2483 (domestic) or 1-785-838-9284 (international) and using the\nconference ID: VERRICA. Participants are asked to dial in 10 minutes before\nthe start of the call to register.\n\nA live audio webcast of the call can also be accessed by visiting the investor\nrelations section of the Company’s website, www.verrica.com, or by clicking\nhere\n(https://www.globenewswire.com/Tracker?data=sEDxNJdnXkZZUA9CqR3UvUCq_HPVKbV4p3w3fM8NJvzyUKE_8lpzr8r43GRjp0L1yVch3RRd_AY8etpctiM9oMG0YVJsKBTxGprDcDwhSA4ZOBbZEjyIqcNphMqV1EgEdoOkG1Zeipb1JMy876fDbg==).\nA replay of the webcast will be archived on Verrica’s website for 90 days\nfollowing the event.\n\nAbout Verrica Pharmaceuticals Inc. \nVerrica is a therapeutics company developing and commercializing medications\nfor the treatment of dermatological diseases, including skin cancers.\nVerrica’s product YCANTH(®) (VP-102) (cantharidin), is the first and only\nhealthcare professional-administered treatment approved by the FDA to treat\nadult and pediatric patients two years of age and older with molluscum\ncontagiosum, a highly contagious viral skin infection affecting approximately\n6 million people in the United States, primarily children.\nYCANTH(®) (VP-102) is also in development to treat common warts, the largest\nremaining unmet need in medical dermatology. Verrica has also entered a\nworldwide license agreement with Lytix Biopharma AS to develop and\ncommercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315)\nfor non-melanoma skin cancers including basal cell carcinoma and squamous cell\ncarcinoma.  For more information, visit www.verrica.com.\n\nFOR MORE INFORMATION, PLEASE CONTACT:\n\nInvestors:\n\nJohn J Kirby \nInterim Chief Financial Officer \njkirby@verrica.com\n\nKevin Gardner \nLifeSci Advisors \nkgardner@lifesciadvisors.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/4938c2eb-43f1-4f6c-a1e1-82ab7fb66c3b)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3nMDsV","title":"Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026","author":"Globe Newswire","ticker":"VRCA","created":"2026-05-05T12:00:00.843Z","tickers":["VRCA"],"exchange":"NASDAQ","article_body":"WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals\nInc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics\ncompany developing and commercializing medications for the treatment of\ndermatological diseases, including skin cancers, today announced that it will\nhost a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 12,\n2026, to discuss the Company's financial results for the first quarter ending\nMarch 31, 2026, and provide a corporate update.\n\nIndividuals may participate in the live call via telephone by dialing\n1-833-316-2483 (domestic) or 1-785-838-9284 (international) and using the\nconference ID: VERRICA. Participants are asked to dial in 10 minutes before\nthe start of the call to register.\n\nA live audio webcast of the call can also be accessed by visiting the investor\nrelations section of the Company’s website, www.verrica.com, or by clicking\nhere\n(https://www.globenewswire.com/Tracker?data=sEDxNJdnXkZZUA9CqR3UvUCq_HPVKbV4p3w3fM8NJvzyUKE_8lpzr8r43GRjp0L1yVch3RRd_AY8etpctiM9oMG0YVJsKBTxGprDcDwhSA4ZOBbZEjyIqcNphMqV1EgEdoOkG1Zeipb1JMy876fDbg==).\nA replay of the webcast will be archived on Verrica’s website for 90 days\nfollowing the event.\n\nAbout Verrica Pharmaceuticals Inc. \nVerrica is a therapeutics company developing and commercializing medications\nfor the treatment of dermatological diseases, including skin cancers.\nVerrica’s product YCANTH(®) (VP-102) (cantharidin), is the first and only\nhealthcare professional-administered treatment approved by the FDA to treat\nadult and pediatric patients two years of age and older with molluscum\ncontagiosum, a highly contagious viral skin infection affecting approximately\n6 million people in the United States, primarily children.\nYCANTH(®) (VP-102) is also in development to treat common warts, the largest\nremaining unmet need in medical dermatology. Verrica has also entered a\nworldwide license agreement with Lytix Biopharma AS to develop and\ncommercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315)\nfor non-melanoma skin cancers including basal cell carcinoma and squamous cell\ncarcinoma.  For more information, visit www.verrica.com.\n\nFOR MORE INFORMATION, PLEASE CONTACT:\n\nInvestors:\n\nJohn J Kirby \nInterim Chief Financial Officer \njkirby@verrica.com\n\nKevin Gardner \nLifeSci Advisors \nkgardner@lifesciadvisors.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/4938c2eb-43f1-4f6c-a1e1-82ab7fb66c3b)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-05T12:00:00.886037805Z","server_sent_at_ms":1777982400886},"received_at":"2026-05-05T12:00:00.968Z","source_url":"https://www.globenewswire.com/news-release/2026/03/11/3253711/0/en/verrica-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results.html"},"analysis":{"id":"15432","press_release_id":"20875","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"earnings","narrative":"Verrica Pharmaceuticals announced it will report Q1 2026 financial results and provide a corporate update on May 12, 2026, via conference call.\n\nThe call is scheduled for 4:30 p.m. ET and will be accessible via webcast on the company's investor relations website.\n\nVerrica's current commercial product is YCANTH for molluscum contagiosum, and it is developing VP-315 for non-melanoma skin cancers.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Standard earnings call announcement; no new financial data."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"John J Kirby","role":"Interim Chief Financial Officer"},{"name":"Kevin Gardner","role":"LifeSci Advisors"}],"products":["YCANTH(®) (VP-102)","cantharidin","VP-315 (ruxotemitide)","LTX-315","VP-LTX-315"],"companies":[{"name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA"},{"name":"Lytix Biopharma AS","relationship":"partner"},{"name":"LifeSci Advisors","relationship":"IR contact"},{"name":"GlobeNewswire, Inc.","relationship":"wire service"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a standard earnings announcement/invitation for a conference call. No financial results or guidance are disclosed yet; it is purely a logistical notice."},"tickerRelevance":{"others":[],"primary":"VRCA"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"earnings-announcement-logistics","sectorWeight":"biotech"}},"event_type":"earnings","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Verrica Pharmaceuticals announced it will report Q1 2026 financial results and provide a corporate update on May 12, 2026, via conference call.\n\nThe call is scheduled for 4:30 p.m. ET and will be accessible via webcast on the company's investor relations website.\n\nVerrica's current commercial product is YCANTH for molluscum contagiosum, and it is developing VP-315 for non-melanoma skin cancers.","key_figures":{},"named_entities":{"people":[{"name":"John J Kirby","role":"Interim Chief Financial Officer"},{"name":"Kevin Gardner","role":"LifeSci Advisors"}],"products":["YCANTH(®) (VP-102)","cantharidin","VP-315 (ruxotemitide)","LTX-315","VP-LTX-315"],"companies":[{"name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA"},{"name":"Lytix Biopharma AS","relationship":"partner"},{"name":"LifeSci Advisors","relationship":"IR contact"},{"name":"GlobeNewswire, Inc.","relationship":"wire service"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-05T13:09:53.175Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"earnings-announcement-logistics","sectorWeight":"biotech"}},"durationMs":84883,"modelName":"glm-4.7"}}